Treatment of superior vena cava syndrome using AngioJet™ thrombectomy system
Superior vena cava syndrome is a relatively rare presentation in which diminished venous return to the heart produces congestion of the neck, face and upper extremities. Typically, a mediastinal mass produces external compression on the superior vena cava and reduces venous return. However, superior vena cava syndrome can present acutely in the setting of vena cava thrombosis. Multiple scoring systems are available to assist clinicians with appropriate timing of interventions for SVC syndrome. When specific criteria are met, endovascular intervention can be beneficial to patients to prevent rapid deterioration.
A 75-year-old female with no significant past medical history presented to the emergency department with increased facial swelling, nausea and vomiting which began the night prior to presentation. The patient underwent a CT chest which revealed a 3.2 × 3.0 × 3.8 cm spiculated mass compressing the right main bronchus and right pulmonary artery. The patient was intubated and interventional radiology was consulted. The patient underwent venography which showed extensive thrombosis of the innominate veins. Rheolytic thrombectomy with AngioJet™ was performed to alleviate clot burden and minimize risk of secondary pulmonary embolism. Kissing stents were placed in the bilateral innominate veins to maintain patency after thrombectomy. After the procedure, the patient was successfully extubated and had near complete resolution of facial swelling approximately 12 h post procedure. A follow up venogram performed on post procedure day 4 showed patent bilateral subclavian, innominate, and internal jugular veins as well as a patent superior vena cava.
Acute occlusion of superior vena cava can present with life threatening symptoms such as loss of airway. AngioJet™ thrombectomy is another tool available to interventional radiologists when a patient’s clinical condition necessitates treatment.
KeywordsSVC syndrome AngioJet Rheolytic Thrombectomy
catheter directed thrombolysis
percutaneous coronary intervention
superior vena cava
Superior vena cava (SVC) syndrome occurs when drainage from the head and upper extremities becomes significantly reduced, leading to venous congestion. Symptoms include facial plethora, swelling of the neck and extremities, dyspnea and visual disturbances. When symptoms are rapidly progressive, the etiology is most commonly an underlying malignancy, such as a primary pulmonary tumor or metastatic disease (Lauten et al. 2010). When a patient presents with acute SVC syndrome and has critical symptoms such as airway compromise, interventional radiologists are frequently consulted for management. To manage patients successfully in short term, options include angioplasty, mechanical thrombectomy, thrombolysis and venous stenting (Dib and Hennebry 2012). With our patient, we chose to perform AngioJet™ (Boston Scientific, Marlborough, MA) rheolytic thrombectomy in conjunction with kissing stents to alleviate acute venous congestion and decrease thrombotic burden that could become pulmonary emboli (Ptohis et al. 2015). This method provides immediate decompression of the obstruction and maintains patency of the superior vena cava when external compression from a tumor was likely the cause of thrombosis.
Due to the presence of thrombus within the bilateral internal jugular veins, a decision was made to access the right common femoral vein to allow for bilateral internal jugular vein intervention. Under ultrasound guidance, the right common femoral vein was punctured and an 8 French, 70 cm vascular sheath was placed using standard Seldinger technique with distal tip at the SVC-atrial junction. A 5 French Berenstein catheter was advanced beyond the narrowing of the cavoatrial junction and the bilateral internal jugular veins were successfully selected. Venography was performed which demonstrated the narrowing at the cavoatrial junction as well as extensive thrombus within the SVC, right internal jugular, left subclavian, left innominate, and left internal jugular veins with multiple collateral vessels draining centrally. The compression extended to the origin of the innominate vein. The Glidewire was exchanged for an Amplatz wire, with distal tip positioned within the left internal jugular vein. Due to the extensive thrombus burden and pre-existing pulmonary compromise, the decision was made to perform pharmacothrombolysis prior to establishing outflow.
At our institution, the EKOS infusion catheter (EKOS Corporation, Bothell, WA) and AngioJet™ ZelanteDVT thrombectomy system (Boston Scientific, Marlborough, MA) are available for clinical use. Catheter directed thrombolysis has high clinical success and long-term patency. The AngioJet™ thrombectomy catheter system was chosen because it facilities high dose thrombolytic infusion in a short period of time in the power pulse mode. This allows rapid dubulking of thrombus to prevent iatrogenic pulmonary emboli.
The existing Berenstein catheter in the right internal jugular vein from right common femoral vein access was exchanged for the 8 French AngioJet™ ZelanteDVT catheter. The 8 French AngioJet™ ZelanteDVT infusion catheter was advanced into the bilateral internal jugular veins and thrombolysis was performed using 10 mg tPA diluted in 100 mL of normal saline using the power pulse mode. During thrombolysis, the patient developed a brief episode of brachycardia which resolved upon pausing the AngioJet™ system. When the patient returned to a sinus rhythm, thrombolysis was continued for a total of approximately 3 min. Repeat angiography demonstrated decrease in thrombus burden and the AngioJet™ catheter was removed.
To establish outflow and overcome the extrinsic compression from the pulmonary mass, the decision was made to place kissing stents from the SVC into the bilateral brachiocephalic veins. Over the right basilic vein Amplatz wire, a 12 mm × 4 cm uncovered stent (Bard, New Providence, NJ) was placed across the cavoatrial narrowing along the length of the right innominate vein. Via the right common femoral vein, a 12 mm × 6 cm stent was placed across the cavoatrial narrowing and extending into the left subclavian vein. The stents were subsequently dilated using a 14 mm × 6 cm angioplasty balloon. Post stenting venography demonstrated persistent narrowing above the level of the right innominate vein. A second, 12 mm × 4 cm uncovered stent was advanced over the right basilic vein Amplatz wire. Final venography demonstrated improved flow through the bilateral jugular veins. The procedure was completed successfully and the patient returned to the ICU. The heparin infusion was continued post procedurally.
Superior vena cava syndrome affects approximately 15,000 patients per year (Seligson and Surowiec 2019). The majority of cases are secondary to metastatic lung cancer with line associated thrombosis from central venous catheters and cardiac pacemakers as iatrogenic sources of SVC syndrome (Straka et al. 2016). The endovascular approach can achieve rapid symptomatic relief in benign and malignant causes of SVC syndrome. However, the long term results following stent placement are unknown and rethrombosis rates can be significant. Despite these potential shortcomings, endovascular techniques are the accepted first-line therapy for SVC syndrome (Kalra et al. 2018).
Several treatment options exist in the literature. Catheter directed thrombolysis (CDT) was first introduced as a modality to treat peripheral thrombi and has since been used to treat extensive thrombus within the superior vena cava (Ghanavati et al. 2017; Dotter et al. 1974). However, most examples in the literature combine percutaneous transarterial (PTA) techniques using 10 to 16 mm angioplasty balloons with stents (Kalra et al. 2018). The largest case series available in the literature for malignant SVC syndrome showed approximately 79% clinical patency with CDT and stent placement over an average 7 month follow up (Kee et al. 1998). Small perforations can occur which can be managed with prolonged balloon inflation. If SVC rupture occurs, pericardial tamponade must be rapidly diagnosed and treated with ultrasound guided pericardial drainage as necessary.
The first iteration of AngioJet™ was approved in 1996 for arteriovenous access graft thrombectomy as an alternative to traditional Fogarty-type catheters (US Food and Drug Administration 1996). Rheolytic thrombolysis uses a high-pressure infusion pump forcing saline through a 5 French rapid exchange catheter. The system’s catheter has a double lumen; a smaller one to run saline distally and a larger one to collect aspirated material. The saline solution exits the tip at approximately 500 km/h to create a circumferential zone of depression by the Bernoulli effect which crumples and aspirates thrombus (Petronio et al. 2010). Rheolytic thrombectomy has since been widely adapted for percutaneous coronary intervention (PCI) and treatment for lower extremity deep vein thrombosis (Antoniucci et al. 2004; Garcia et al. 2015; Leung et al. 2015; Elgendy et al. 2017).
A limited number of cases of rheolytic thrombectomy for SVC syndrome are available in the literature. AngioJet™ was used to treat SVC syndrome following orthotopic heart transplant for hypoplastic left heart syndrome. This pediatric patient underwent primary end-to-end anastomosis at the vena cava because of a previously performed Fontan procedure. Anastomosis at the vena cava predisposed the patient to acute stenosis at the vena cava. The patient was treated with rheolytic thrombectomy for approximately 47 s and 10 mm balloon angioplasty. The patient was started on warfarin therapy for 2 weeks and did not shows signs of recurrent obstruction or other thrombotic events at 6 months (Sessions et al. 2016).
After an extensive literature search, our case represents the second published use of AngioJet™ thrombectomy to treat SVC syndrome. Similar to the previously published case, our patient had no residual symptoms of SVC syndrome following the procedure. The patient established follow up at an outside institution for continued oncologic care.
Rheolytic thrombectomy for SVC syndrome is currently an off-label indication for AngioJet™. When faced with potentially life-threatening conditions, the interventional radiologist should consider all options available for treatment. Investigational data, reports within the literature and clinical experience should guide patient specific treatment. Our experience with AngioJet™ demonstrates its applicability for SVC syndrome with short term technical and clinical success.
AR reviewed the case and was the primary manuscript author. JC provided supporting articles and literature for manuscript. MK reviewed clinical documents such as H&P and consult notes. EL reviewed and edited technical details of the performed procedure. NA reviewed and edited the literature review. All authors read and approved the final manuscript.
The authors did not receive any funding for this publication.
Ethics approval and consent to participate
Our institutional review board waived formal approval for a case report.
Consent for publication
Prior to the procedure, the patient provided written consent for publication of their medical case and accompanying medical imaging and clinical photographs, to be used for research purposes published in print and electronically. The signed consent was uploaded to the institution’s electronic medical record and is available upon request.
The authors declare that they have no competing interests.
- Garcia MJ, Lookstein R, Malhotra R et al (2015) Endovascular Management of Deep Vein Thrombosis with Rheolytic Thrombectomy: final report of the prospective multicenter PEARL (peripheral use of AngioJet Rheolytic Thrombectomy with a variety of catheter lengths) registry. J Vasc Interv Radiol 26(6):777–785CrossRefGoogle Scholar
- Seligson MT, Surowiec SM (2019) Superior Vena Cava Syndrome. FL, Treasure Island https://www.ncbi.nlm.nih.gov/books/NBK441981/. Accessed 1 May 2019
- US Food and Drug Administration (1996) Possis AngioJet® rapid Thrombectomy system. FDA 510(k) Premarket Notification:20–25. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=K960970.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.